Sheng-Nan Lu

Chang Gung Memorial Hospital, T’ai-pei, Taipei, Taiwan

Are you Sheng-Nan Lu?

Claim your profile

Publications (232)1019.91 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are effective antivirals recommended as first-line monotherapies for chronic hepatitis B (CHB). This study aimed to compare the short-term efficacy between TDF and ETV in the treatment of CHB with severe acute exacerbation. From 2008 to 2013, 189 consecutive treatment-naïve CHB patients receiving TDF (n=41) or ETV (n=148) for severe acute exacerbation were enrolled. The primary endpoint was overall mortality or receiving liver transplantation by week 24. The baseline characteristics were comparable between these two groups. By week 24, eight (19%, 95% confidence interval (CI):7%-32%) patients in the TDF group and twenty-six (18% (11-24%)) patients in the ETV group died (n=30) or received liver transplantation (n=4) (p=0.749). Both groups of patients developed similar rates of liver-related complications, and achieved comparable biochemical and virological response at week 24. Cox regression analysis showed that baseline viral DNA level (p=0.002), hypertension (p=0.002), model for end-stage liver disease (MELD) score (p=0.01), platelet count (p=0.005), early presence (within 4 weeks) of ascites (p=0.005), hepatic encephalopathy (p=0.002) and hepatorenal syndrome (p<0.001) were independent factors for mortality or liver transplantation. Among patients who survived by week 24, there was no difference in serum creatinine increase≥0.5 mg/dL from baseline between two groups (6.7% (0%-16%) vs. 2.0% (0%-4.8%), p=0.231), whereas significant reduction of estimated glomerular filtration rate (eGFR) was found in both groups (p=0.001 and p=0.001, respectively). In conclusion, TDF and ETV produce similar treatment response and clinical outcomes in patients with severe acute exacerbation of CHB. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Antimicrobial Agents and Chemotherapy 03/2015; DOI:10.1128/AAC.00261-15 · 4.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study was to elucidate longitudinally quantitative changes of hepatitis B virus (HBV) surface antigen (HBsAg) and HBV DNA in elder HBsAg carriers in a community. Among 1002 residents screened for HBsAg in 2005, 405 responded to this follow-up study in 2010. Fifty-nine (14.6%) were HBsAg carriers in 2005; HBsAg quantification and HBV DNA were measured. HBsAg quantification (cutoff 1600 IU/mL) and HBV DNA (cutoff 2000 IU/mL) were combined to stratify the participants between two screens. A total of 30 men and 29 women with a mean age of 63.9 ± 7.9 years were enrolled. Quantitative levels of HBsAg and HBV DNA were significantly correlated in 2005 (r = 0.509, p < 0.001) and 2010 (r = 0.777, p < 0.001). Concentrations of HBsAg (IU/mL) significantly decreased from 2.2 ± 1.0 log in 2005 to 1.7 ± 1.5 log in 2010 (p < 0.001). The level of HBsAg was decreased in 48 (81.4%) individuals and HBsAg was undetectable in eight (13.6%). The annual incidence of HBsAg clearance was 2.7%. These 59 HBsAg carriers in 2005 were divided into four groups: low HBsAg low HBV DNA (n = 32), high HBsAg low HBV DNA (n = 5), low HBsAg high HBV DNA (n = 12) and high HBsAg high HBV DNA (n = 10). All 32 individuals in the low HBsAg low HBV DNA group were still in that group in 2010, whereas only two of the high HBsAg high HBV DNA group became inactive. As with a younger cohort in hospital, HBsAg quantification was still well correlated with HBV DNA in elderly HBsAg carriers in the community. Lower levels of both HBsAg and HBV DNA might represent an inactive HBV infection. Copyright © 2014. Published by Elsevier Taiwan.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Polymorphisms in IFNL3 (encodes interferon λ3 or IL28B) are associated with outcomes of treatment for hepatitis C virus (HCV) infection. However, there is controversy over how polymorphisms in IFNL3 affect risk for development of hepatocellular carcinoma (HCC) in patients treated with pegylated interferon and ribavirin. In a retrospective study, we analyzed data from 1118 patients with HCV infection (589 men; median age, 60 years; 49.9% infected with genotype 1; 51.3% with advanced fibrosis) treated with pegylated interferon and ribavirin from March 2000 through October 2009 at the Chang Gung Memorial Hospital in Kaohsiung, Taiwan (71.64% achieved sustained virologic response [SVR]). Baseline samples were collected before therapy. Starting 24 weeks after treatment, clinical and biochemical features were assessed every 3-6 months and patients underwent ultrasound examinations. Lesions detected were examined by computed tomography, angiography, or fine-needle aspiration biopsy analyses. Patients were followed from the initiation of HCV therapy until diagnosis of HCC (based on published guidelines), death, or March 31, 2013 (median, 60 months). DNA samples from each patient were analyzed for rs12979860 in IFNL3. Kaplan-Meier analysis was used to determine risk for development of HCC. The percentages of patients with the IFNL3 rs12979860 CC, CT, and TT genotypes were 86.4 %, 13.2%, and 0.3%, respectively. One hundred and eight patients (9.66%) developed HCC. The IFNL3 rs12979860 CT and TT genotypes correlated with high baseline levels of α-fetoprotein (AFP; ≥20 ng/mL), advanced stage of fibrosis, diabetes, or lack of an SVR (all P<.05). Based on multivariate Cox regression analysis, age ≥60 years, low platelet count (<15×10(9) cells/L), AFP ≥20 ng/mL, advanced-stage fibrosis, diabetes, lack of an SVR, and the IFNL3 rs12979860 CT and TT genotypes were significant risk factors for HCC (P<.05). Age ≥60 years, high numbers of platelets or levels of AFP, and advanced fibrosis were risk factors for HCC among patients with SVRs. IFNL3 rs12979860 genotype did not have a significant effect on risk for HCC among patients with SVRs, although some of these patients (with the CT or TT genotype) did develop HCC. Among patients without SVRs, only fibrosis stage and the IFNL3 rs12979860 CT and TT genotypes (hazard ratio, 1.80; 95% confidence interval, 1.06-3.07; P=.030) were independent risk factors for HCC. Based on a retrospective study of patients treated for HCV infection, the IFNL3 rs12979860 CT and TT polymorphisms are associated with risk for HCC, especially in patients without SVRs. Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.
    Clinical Gastroenterology and Hepatology 11/2014; DOI:10.1016/j.cgh.2014.10.035 · 6.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study investigates the impact of general anesthesia (GA) on percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). A total of 118 treatment-naïve HCC patients in Barcelona Clinic Liver Cancer curative stage were enrolled. Patients who underwent RFA with GA were designated as the GA group, and the others were identified as the non-GA group. All the percutaneous RFA procedures were performed by the same hepatologist. The GA group comprised 42 (44.1%) patients with 71 tumors (mean size, 2.53 cm) and the non-GA group had 66 patients (55.9%) with 90 tumors (mean size, 2.35 cm). Complete tumor ablation was achieved after one session in 92.3% of the 52 GA patients, and after one to three sessions in 92.4% of 66 non-GA patients. The GA group required significantly fewer RFA sessions to obtain a similar treatment effect (p < 0.001) and the duration of hospitalization was also shortened among the GA patients (4.4 ± 0.9 days vs. 5.1 ± 1.9 days, p = 0.044). The 2-year overall survival and recurrence-free survival rates were not significantly different between the two groups. Overall, performing RFA with GA can decrease the number of sessions required to achieve complete tumor ablation in early stage HCC patients and shorten the hospitalization duration.
    The Kaohsiung journal of medical sciences 07/2014; DOI:10.1016/j.kjms.2014.07.001 · 0.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion. Methods A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous HBeAg seroconversion, respectively, were analyzed. Results Compared to spontaneous HBeAg seroconverters, more IFN-induced HBeAg seroconverters were males (p = 0.004). For all patients, the IFN-induced HBeAg seroconverters faced a higher risk of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconverters (p Conclusions IFN-induced rather than spontaneous HBeAg seroconversion was associated with higher risk of HBV reactivation and HBeAg seroreversion, especially in patients who were older than 30 years at HBeAg seroconversion.
    Hepatology International 07/2014; 8(3):365-374. DOI:10.1007/s12072-014-9542-8 · 2.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Quantification of hepatitis B surface antigen (HBsAg) has been suggested to be helpful in the management of chronic hepatitis B (CHB) patients. Nucleos(t)ide analogs (NAs) are the therapy of choice for CHB and are used in the majority of CHB patients. NAs are able to induce hepatitis B virus (HBV) viral suppression, normalization of alanine aminotransferase (ALT) levels, and improvement in liver histology. Automated quantitative assays for serum HBsAg have recently become available, facilitating standardized quantification of serum HBsAg. This has led to increased interest in the clinical application of quantitative serum HBsAg for predicting therapeutic response to NAs. Recent studies have shown that a decline in serum HBsAg levels in patients receiving peginterferon may signal successful induction of immune control over HBV, and can therefore be used to predict therapeutic response. NA treatment typically induces a less rapid decline in HBsAg than interferon treatment; it has been estimated that full HBsAg clearance can require decades of NA treatment. However, a rapid HBsAg decline during NA therapy may identify patients who will show clearance of HBsAg. Currently, there is no consensus on the clinical utility of serum HBsAg monitoring for evaluating patient responses to NA therapy. This review focuses on recent findings regarding the potential application of HBsAg quantification in the management of CHB patients receiving NA therapy.
    World Journal of Gastroenterology 06/2014; 20(24):7686-7695. DOI:10.3748/wjg.v20.i24.7686 · 2.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Obesity is considered a risk factor for hepatocellular carcinoma (HCC); The relationship between adipocytokine and HCC in hepatitis B virus (HBV) carriers remains unclear. We prospectively investigated the association of adiponectin, leptin and visfatin levels with HCC. Methods: We conducted a nested case-control study in a community-based cohort with 187 incident HCC and 374 HCC-free HBV carriers. Unconditional logistic regression was conducted to estimate the odds ratios and 95 percent confidence intervals. Results:Adiponectin, but not leptin and visfatin, levels were associated with an increased risk of HCC after adjustment for other metabolic factors and HBV related factors. The risk was increased (OR=0.51, 95% CI=0.12 - 2.11;OR=4.88 (1.46 - 16.3); OR=3.79 (1.10 - 13.0); OR=4.13 (1.13 - 15.1) with each additional quintiles, respectively) with a significant dose-response trend (ptrend =0.003). HCC risk associated with higher adiponectin level was higher in HBV carriers with ultrasonographic fatty liver, with genotype C infection, with higher viral load and with elevated alanine aminotransferase. Longitudinally, participants with higher adiponectin were less likely to achieve HBsAg seroclearance and more likely to have persistently higher HBV DNA. Eventually, they were more likely to develop liver cirrhosis (OR=1.65 (0.62 - 4.39); OR=3.85 (1.47 - 10.1); OR=2.56 (0.96 - 6.84); OR=3.76 (1.33 - 10.7) for the 2nd, 3rd, 4th and 5th quintiles, respectively; ptrend= 0.017) before HCC. Conclusions:Elevated adiponectin levels were independently associated with an increased risk of HCC. Impact: Adiponectin may play different role in the virus-induced and metabolic related liver diseases, but the underline mechanism remains unknown.
    Cancer Epidemiology Biomarkers & Prevention 06/2014; 23(8). DOI:10.1158/1055-9965.EPI-14-0161 · 4.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & Aims We compared the mortality and treatment response between lamivudine (LAM) and entecavir (ETV) in chronic hepatitis B (CHB) patients with severe acute exacerbation and hepatic decompensation. Methods From 2003 to 2010 (LAM group) and 2008 to 2010 (ETV group), 215 and 107 consecutive CHB naïve patients with severe acute exacerbation and hepatic decompensation treated with LAM and ETV respectively, were recruited. Results At baseline, LAM group had higher AST levels and end-stage liver disease (MELD) scores, and lower albumin levels than ETV group. Univariate analysis showed that LAM group had a higher rate of overall (p=0.02) and liver-related mortality (p=0.052) at week 24 than ETV group, including in patients with acute-on-chronic liver failure. Multivariate analysis showed that MELD scores, ascites, and hepatic encephalopathy were independent factors for overall and liver-related mortality at week 24. ETV or LAM treatment was not an independent factor for mortality in all patients or patients with acute-on-chronic liver failure. The best cut-off value of MELD scores were 24 for 24-week liver-related mortality. ETV group achieved better virological response (HBV DNA<300 copies/mL) than LAM group at week 24 (p=0.043) and 48 (p=0.007). T1753C/A mutation was also an independent predictor associated with overall and liver-related mortality at week 24. Conclusions The choice between ETV and LAM was not an independent factor for mortality in CHB patients with acute exacerbation and hepatic decompensation. Patients with ascites, hepatic encephalopathy, and MELD scores ⩾24 were associated with poor outcome and should be considered for liver transplantation.
    Journal of Hepatology 06/2014; DOI:10.1016/j.jhep.2014.02.013 · 9.86 Impact Factor
  • Brian I. Carr, Chih-Yun Lin, Sheng-Nan Lu
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Small HCCs usually arise in cirrhosis, often with associated thrombocytopenia. Many large HCC patients have normal blood platelet counts. Aims To compare parameter and phenotype patterns of patients with small <3cm and larger HCCs. Methods Retrospective analysis was undertaken of a 4139 patient HCC database to compare patient demographics, liver and tumor characteristics associated with small and large size HCCs, especially with respect to platelet counts. Results Patients with larger HCCs had more tumor nodules and PVT positivity, and had higher blood AFP, bilirubin and platelet counts. In patients with larger tumors and normal platelets (43.7% of the cohort), tumors were larger and AFP levels were higher, with lower bilirubin and AST levels than in patients with larger tumors and thrombocytopenia (17.5%). A parsimonious multinomial regression model showed high Odds Ratio for AFP and platelets for tumors >3cm with PVT. Conclusions Platelet levels are associated with distinct large HCC phenotypes.
    Seminars in Oncology 06/2014; DOI:10.1053/j.seminoncol.2014.04.001 · 3.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biological and epidemiological data suggest that vitamin D levels may influence cancer development. Several single nucleotide polymorphisms have been described in the vitamin D receptor (VDR) gene in association with cancer risk. We aimed to investigate the association of VDR gene polymorphisms with hepatocellular carcinoma (HCC) development in chronic hepatitis C patients.
    Translational oncology 05/2014; DOI:10.1016/j.tranon.2014.05.001 · 3.40 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A recent study showed that chronic hepatitis B virus (HBV) carriers with nucleos(t)ide analogue (NA)-induced hepatitis B antigen (HBeAg) seroconversion occurring before the age of 30 years have a higher risk of HBV reactivation. To compare the risk of HBV reactivation and HBeAg seroreversion between patients with spontaneous and NA-induced HBeAg seroconversion. A total of 135 and 251 non-cirrhotic patients with NA-induced and spontaneous HBeAg seroconversion, respectively, were analyzed. NA-induced HBeAg seroconverters faced higher risks of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconverters (P < 0.001). In spontaneous HBeAg seroconverters, age at HBeAg seroconversion, sex, HBV DNA levels before HBeAg seroconversion, HBV genotype C, and pre-S deletions were independent predictors of HBV reactivation. In NA-induced HBeAg seroconverters, only age at baseline was an independent predictor of HBV reactivation. To determine whether the difference in the incidence of HBV reactivation or HBeAg seroreversion between two groups was age-specific, we analyzed these patients according to their age at HBeAg seroconversion (20-29, 30-39, and a parts per thousand yen40 years). Our data showed that NA-induced HBeAg seroconversion was an independent predictor of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconversion in patients older than 40 years at HBeAg seroconversion, but not in patients between 20-29 and 30-39 years of age. NA-induced HBeAg seroconverters are associated with higher risks of HBV reactivation and HBeAg seroreversion compared to spontaneous HBeAg seroconverters, especially in patients who are older than 40 years at HBeAg seroconversion.
    Digestive Diseases and Sciences 05/2014; 59(10). DOI:10.1007/s10620-014-3194-3 · 2.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of a risk assessment tool for long-term hepatocellular carcinoma risk would be helpful in identifying high-risk patients and providing information of clinical consultation. The model derivation and validation cohorts consisted of 975 and 572 anti-HCV seropositives, respectively. The model included age, alanine aminotransferase (ALT), the ratio of aspirate aminotransferase to ALT, serum HCV RNA levels and cirrhosis status and HCV genotype. Two risk prediction models were developed: one was for all-anti-HCV seropositives, and the other was for anti-HCV seropositives with detectable HCV RNA. The Cox's proportional hazards models were utilized to estimate regression coefficients of HCC risk predictors to derive risk scores. The cumulative HCC risks in the validation cohort were estimated by Kaplan-Meier methods. The area under receiver operating curve (AUROC) was used to evaluate the performance of the risk models. All predictors were significantly associated with HCC. The summary risk scores of two models derived from the derivation cohort had predictability of HCC risk in the validation cohort. The summary risk score of the two risk prediction models clearly divided the validation cohort into three groups (p<0.001). The AUROC for predicting 5-year HCC risk in the validation cohort was satisfactory for the two models, with 0.73 and 0.70, respectively. Scoring systems for predicting HCC risk of HCV-infected patients had good validity and discrimination capability, which may triage patients for alternative management strategies.
    PLoS ONE 05/2014; 9(5):e94760. DOI:10.1371/journal.pone.0094760 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The influential roles of antibiotic prophylaxis on cirrhotic patients with peptic ulcer bleeding are still not well documented. The purpose of this study is to clarify these influential roles and to identify the risk factors associated with rebleeding, bacterial infection and in-hospital mortality. A cross-sectional, chart review study was conducted on 210 cirrhotic patients with acute peptic ulcer hemorrhage who underwent therapeutic endoscopic procedures. Patients were divided into group A (with prophylactic intravenous ceftriaxone, n = 74) and group B (without antibiotics, n = 136). The outcomes were length of hospital days, prevention of infection, rebleeding rate and in-hospital mortality. Our results showed that more patients suffered from rebleeding and infection in group B than group A (31.6% vs. 5.4%; p<0.001 and 25% vs. 10.8%; p = 0.014 respectively). The risk factors for rebleeding were active alcoholism, unit of blood transfusion, Rockall score, model for end-stage liver disease score and antibiotic prophylaxis. The risk factors for infection were active alcoholism, Child-Pugh C, Rockall score and antibiotic prophylaxis. Rockall score was the predictive factor for in-hospital mortality. In conclusions, antibiotic prophylaxis in cirrhotic patients after endoscopic interventions for acute peptic ulcer hemorrhage reduced infections and rebleeding rate but not in-hospital mortality. Rockall score was the predictive factor of in-hospital mortality.
    PLoS ONE 05/2014; 9(5):e96394. DOI:10.1371/journal.pone.0096394 · 3.53 Impact Factor
    This article is viewable in ResearchGate's enriched format
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & Aims We investigated whether the quantification of hepatitis surface antigen (HBsAg) could predict HBsAg loss or hepatitis B virus (HBV) relapse after stopping lamivudine treatment. Methods A total of 188 naive chronic hepatitis B patients (83 HBeAg-positive, 105 HBeAg-negative patients), who were treated with lamivudine (treatment duration: 89.3±35.9 weeks, range: 52-243 weeks) previously but stopped the treatment for at least 12 months were recruited. Results The cumulative incidence of HBsAg loss and HBV relapse at year 6 after stopping lamivudine treatment was 24% and 65.9% respectively. Cox regression analysis revealed that lower alanine aminotransferase (ALT) at baseline, lower HBsAg levels at the end of treatment, and longer treatment duration were independent predictors for HBsAg loss, and old age, male sex and higher HBsAg levels at the end of treatment were independent predictors for post-treatment HBV relapse. At the end of treatment, the HBsAg cutoff value of 300 IU/mL could predict 55.6% (5/9) HBsAg loss in HBeAg-positive patients. In HBeAg-negative patients, the HBsAg cutoff values of 120 and 200 IU/mL could predict 79.2% (19/24) HBsAg loss and 93.3% (28/30) post-treatment sustained response respectively. Further HBsAg reduction (>0.22 log IU/mL) at month 6 after stopping treatment from the end of treatment was an independent predictor for HBsAg loss after adjusting for HBsAg level at the end of treatment. Conclusions Serum HBsAg level at the end of treatment is a useful predictor to guide the timing of stopping lamivudine treatment in chronic hepatitis B patients.
    Journal of Hepatology 05/2014; DOI:10.1016/j.jhep.2014.04.029 · 9.86 Impact Factor
  • Source
    Journal of Hepatology 04/2014; 60(4):902–903. DOI:10.1016/j.jhep.2013.12.007 · 10.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver stiffness measurement (LSM) using transient elastography has been proposed to assess liver fibrosis well in various liver diseases. This study was to determine the changes of LSM and its associated factors for chronic hepatitis B (CHB) patients undergoing Entecavir therapy. Consecutive CHB patients underwent Entecavir therapy with two LSMs were enrolled. Patients with aspartate transaminase (AST) and/or alanine transaminase ≧200 IU/L were excluded. The retrospective study enrolled 233 patients including 132 without cirrhosis (group 1) and 101 with cirrhosis (group 2). The mean values of initial liver stiffness were 7.9 and 16.6 kPa for patients in group 1 and group 2, respectively (p<0.001). In addition to the decline of transaminase levels, there was significant reduction of liver stiffness value in a mean interval of 52.8 and 61.9 weeks between the two LSMs for patients in group 1 and 2, respectively (p<0.001). Multivariate analysis showed that higher initial LSM value and presence of hepatitis B e-antigen were associated with a greater decline of LSM value, whereas follow-up AST≧40 IU/L with increased LSM value for group 1 patients. For group 2 patients, longer interval between the two LSMs, higher initial LSM value and AST≧40 IU/L were associated with a greater decline of LSM value, whereas presence of diabetes mellitus (DM) contributed to increased LSM value. In conclusion, CHB patients improved their LSM values after Entecavir therapy. Higher initial LSM value contributed to greater LSM reduction. However, in cirrhotic patients, DM was associated with an increased LSM value after therapy.
    PLoS ONE 03/2014; 9(3):e93160. DOI:10.1371/journal.pone.0093160 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background and Aims: Spontaneous seroclearance of hepatitis B e antigen (HBeAg) and HBV DNA undetectability are important milestones of chronic hepatitis B and major treatment endpoints of antiviral therapy. This study investigates the role of serum hepatitis B surface antigen (HBsAg) levels and establishes prediction models for predicting HBeAg seroclearance and HBV DNA undetectability. Methods: A total of 2139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naïve participants without liver cirrhosis at study entry were included. Spontaneous HBeAg seroclearance and HBV DNA undetectability were analyzed in 431 HBeAg-seropositive participants, and 1708 HBeAg-seronegative participants, respectively. Regression coefficients of predictors in Cox proportional hazard models were converted into integer scores for predicting seroclearance, and predictive accuracy was assessed with time-dependent ROC curves. Results: HBV DNA level was the most important predictor of HBeAg seroclearance, but Serum HBsAg level was the most significant predictor of HBV DNA undetectability. Compared to individuals with HBsAg levels ≥10,000 IU/mL, the multivariate-adjusted rate ratio (95% confidence interval) of HBV DNA undetectability was 1.20 (0.62-2.30), 2.49 (1.31-4.75), and 6.08 (3.19-11.61) for those with serum HBsAg levels of 1000-9999, 100-999, and <100 IU/mL, respectively. The AUROCs of the prediction models for predicting the five- and ten-year probabilities of HBeAg seroclearance and HBV DNA undetectability were 0.85 (0.80-0.90) and 0.78 (0.73-0.83) for HBeAg seroclearance, and 0.77 (0.72-0.82) and 0.73 (0.70-0.76) for HBV DNA undetectability. Conclusion: Prediction models incorporating important host and virus factors can predict HBeAg seroclearance and HBV DNA undetectability. Serum HBsAg levels rather than HBV DNA is the most important predictor of spontaneous HBV DNA undetectability. Serum HBsAg levels should be monitored in the management of patients with HBeAg-seronegative chronic hepatitis B. (Hepatology 2014;).
    Hepatology 02/2014; 60(1). DOI:10.1002/hep.27083 · 11.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advanced hepatocellular carcinoma (HCC) remains a fatal disease even in the era of targeted therapies. Intra-arterial chemotherapy (IACT) can provide therapeutic benefits for patients with locally advanced HCC who are not eligible for local therapies or are refractory to targeted therapies. The aim of this retrospective study was to analyze the effect of IACT with cisplatin and doxorubicin on advanced HCC. Methods. Patients with advanced HCC who were not eligible for local therapies or were refractory to sorafenib received doxorubicin (50 mg/m(2)) and cisplatin (50 mg/m(2)) infusions into the liver via the transhepatic artery. Between January 2005 and December 2011, a total of 50 patients with advanced HCC received this treatment regimen. The overall response rate (ORR) was 22% in all treated patients. In patients who received at least 2 cycles of IACT, the ORR was 36.7%, and the disease control rate was 70%. Survival rate differed significantly between patients who received only one cycle of IACT (group I) and those who received several cycles (group II). The median progression-free survival was 1.3 months and 5.8 months in groups I and II, respectively (P < 0.0001). The median overall survival was 8.3 months for all patients and was 3.1 months and 12.0 months in groups I and II, respectively (P < 0.0001). The most common toxicity was alopecia. Four patients developed grade 3 or 4 leukopenia. Worsening of liver function, nausea, and vomiting were uncommon side effects. This study demonstrated clinical efficacy and tolerable side effects of repeated IACT with doxorubicin and cisplatin in advanced HCC. Our regimen can be an alternative choice for patients with adequate liver function who do not want to receive continuous infusion of IACT.
    01/2014; 2014:160138. DOI:10.1155/2014/160138
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We aimed to determine whether neutrophil-to-lymphocyte ratio (NLR) could be a predictor of antiviral response in chronic hepatitis C patients. A total of 602 consecutive patients (genotype 1, n = 263; genotype 2, n = 297; others/unknown, n = 42) receiving response-guided therapy with peginterferon plus ribavirin were recruited. NLR was related to clinical and virological features and to treatment outcome. Rapid virological response (RVR) and sustained virological response (SVR) were achieved in 436 (73%) and 458 (76%) of the patients, respectively. Higher NLR (≥1.42) was found to be associated with higher prevalence of DM (P = 0.039) and higher hepatitis C viral load (P = 0.002) and white cell count (P < 0.001). NLR was significantly lower in patients with RVR and SVR compared to those without (P = 0.032 and 0.034, resp.). However, NLR was not an independent factor by multivariate analysis. In the subgroup analysis, higher NLR (≥1.42) (odds ratio, 0.494, P = 0.038) was an independent poor predictor of SVR in genotype 2 patients but was not in genotype 1 patients. In conclusion, NLR is a simple and easily accessible marker to predict response to peginterferon plus ribavirin therapy for chronic hepatitis C genotype 2.
    Disease markers 01/2014; 2014:462958. DOI:10.1155/2014/462958 · 2.17 Impact Factor

Publication Stats

6k Citations
1,019.91 Total Impact Points

Institutions

  • 2001–2015
    • Chang Gung Memorial Hospital
      • • Division of Hepato-Gastroenterology
      • • Division of Gastroenterology and Hepatology
      • • Division of Occupational Medicine
      • • Department of Internal Medicine
      T’ai-pei, Taipei, Taiwan
  • 2004–2014
    • Chang Gung University
      • Department of Internal Medicine
      Hsin-chu-hsien, Taiwan, Taiwan
  • 2011
    • Hungkuang University
      臺中市, Taiwan, Taiwan
  • 2010
    • Kaohsiung Medical University
      Kao-hsiung-shih, Kaohsiung, Taiwan
  • 2002–2010
    • National Taiwan University
      • Graduate Institute of Epidemiology and Preventive Medicine
      Taipei, Taipei, Taiwan
  • 2008
    • Academia Sinica
      • Genomics Research Center
      Taipei, Taipei, Taiwan
    • Xiamen Chang Gung Hospital
      Amoy, Fujian, China
  • 2003
    • National Defense Medical Center
      • Department of Public Health
      Taipei, Taipei, Taiwan
  • 1998
    • Taiwan Landseed Hospital
      P’ing-tung-chieh, Taiwan, Taiwan